651744-39-7

Basic information

• Product Name: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate
• Synonyms: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate
• CAS NO: 651744-39-7
• Molecular Formula: C₁₃H₂₀N₂O₄
• Molecular Weight: 268.3089
• Mol File: 651744-39-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate(651744-39-7)
• EPA Substance Registry System: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate(651744-39-7)

Safety Data

• Hazardous Substances Data: 651744-39-7(Hazardous Substances Data)

Upstream product

• 651744-38-6 diethyl 3-(propan-2-yl)-1H-pyrrole-2,4-dicarboxylate 
• 5137-55-3 Aliquat 336 
• 2999-46-4 Ethyl isocyanoacetate 

Downstream Products

• 651744-40-0 ethyl 5-isopropyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 

Relevant articles and documents

SUBSTITUTED PYRROLO TRIAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS

The invention relates to substituted pyrrole triazine carboxamide derivatives of formula (I) and to processes for their preparation, and also /to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5- (methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors

A series of substituted 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino) pyrrolo[2,1-f][1,2,4]-triazines was identified as potent and selective inhibitors of the tyrosine kinase activity of the growth factor receptors VEGFR-2 (Flk-1, KDR) and FGFR-1. The enzyme kinetics associated with the VEGFR-2 inhibition of compound 50 (Ki = 52 ± 3 nM) confirmed that the pyrrolo-[2,1-f][1,2,4]triazine analogues are competitive with ATP. Several analogues demonstrated low-nanomolar inhibition of VEGF- and FGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation. Replacement of the C6-ester substituent of the pyrrolo[2,1-f][1,2,4]-triazine core with heterocyclic bioisosteres, such as substituted 1,3,5-oxadiazoles, afforded compounds with excellent oral bioavailability in mice (i.e., 50 Fpo = 79%). Significant antitumor efficacy was observed with compounds 44, 49, and 50 against established L2987 human lung carcinoma xenografts implanted in athymic mice. A full account of the synthesis, structure-activity relationships, pharmacology, and pharmacokinetic properties of analogues within the series is presented.